Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Dabrafenib plus trametinib is approved by the FDA for the treatment of anaplastic Thyroid Cancer (ATC) (BRAF m). This approval is based on data from phase II basket studies (such as the ROAR trial) that demonstrated strong response rates and improved survival compared to historical outcomes in Anaplastic Thyroid Cancer (ATC) (BRAF m). Clinical guidelines now recommend molecular testing for BRAF V600E at ATC diagnosis to inform the use of these targeted agents. The EMA approval covers BRAF V600E-positive solid tumors, including ATC when the mutation is confir…